Source Articles
Sunitinib
Showing 1 study arm
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kao et al. | 2014 | Prospective | Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial | 10.1007/s11523-013-0280-y | Missing | 46 | 64 | 43.2 | Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Melanoma, Kidney cancer, other, HCC, pancreas | oligometastatic | Multi-target TKI | Sunitinib | — | 85 | extra-cranial | lung, liver, bone, LN unspecified, other | visceral (adrenal, thyroid, inferior vena cava, chest wall) | 50 | 40 | 50 | 10 | 10 | 10 | 5 | 4 | 5 | Treatment-rel. | — | — | 15 | any G3: 21 AEs, any G4: 3 AEs, any G5: 2 AEs | any G3: unknown pts, any G4: unknown pts, any G5: 2 pts |
any G3: anemia, neutropenia, LFT abnormalities, thrombocytopenia, nausea/vomiting, bleeding, metabolic abnormalities, increased creatinine, any G4: anemia, thrombocytopenia, any G5: bleeding (of whom 1 pt due to reirradiation given prior to study treatment, not due to SBRT given in study)
|
/
|